TY - JOUR AB - Glioblastoma (GBM) represents the most frequent glial tumor, with almost 3 new cases per 100,000 people per year. Despite treatment, the prognosis for GBM patients remains extremely poor, with a median survival of 14.6 months, and a 5‑year survival less than 5%. It is generally believed that GBM creates a highly immunosuppressive microenvironment, sustained by the expression of immune‑regulatory factors, including inhibitory immune checkpoints, on both infiltrating cells and tumor cells. However, the trials assessing the efficacy of current immune checkpoint inhibitors in GBM are still disappointing. In the present study, the expression levels of several inhibitory immune checkpoints in GBM (CD276, VTCN1, CD47, PVR, TNFRSF14, CD200, LGALS9, NECTIN2 and CD48) were characterized in order to evaluate their potential as prognostic and eventually, therapeutic targets. Among the investigated immune checkpoints, TNFRSF14 and NECTIN2 were identified as the most promising targets in GBM. In particular, a higher TNFRSF14 expression was associated with worse overall survival and disease‑free survival, and with a lower Th1 response. AD - CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, A‑1090 Vienna, Austria IRCCS Centro Neurolesi Bonino Pulejo, I-98124 Messina, Italy Department of Biomedical and Biotechnological Sciences, University of Catania, I-95123 Catania, Italy Department of Medical Sciences, Surgery and Advanced Technologies, University of Catania, I-95123 Catania, Italy AU - Lombardo,Salvo,Danilo AU - Bramanti,Alessia AU - Ciurleo,Rosella AU - Basile,Maria,Sofia AU - Pennisi,Manuela AU - Bella,Rita AU - Mangano,Katia AU - Bramanti,Placido AU - Nicoletti,Ferdinando AU - Fagone,Paolo DA - 2020/12/01 DO - 10.3892/ol.2020.12195 IS - 6 JO - Oncol Lett KW - glioblastoma immune checkpoint inhibitory check-points astrocytoma CD276 VTCN1 CD47 PVR TNFRSF14 CD200 LGALS9 NECTIN2 CD48 PY - 2020 SN - 1792-1074 1792-1082 SP - 332 ST - Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic players T2 - Oncology Letters TI - Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic players UR - https://doi.org/10.3892/ol.2020.12195 VL - 20 ER -